Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | BMC Cancer

Fig. 6

From: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma

Fig. 6

Therapeutic targeting of the FOXM1 genetic network in myeloma. FOXM1 is a proliferation-associated transcription factor that interacts in myeloma cells with the cyclin D-CDK4/6-Rb-E2F pathway, a key regulator of the G1-to-S cell cycle transition. The findings of this study demonstrate that, in addition to cell cycle progression, FOXM1 promotes drug resistance and, possibly, cellular senescence. Another interaction by which FOXM1 may desensitize myeloma to drug inhibition is NEK2. Small-molecule inhibitors of FOXM1, CDK4/6 and NEK2 are indicated. See main text for details

Back to article page